You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

Table 1.  

Parameters CACG group (n = 65) Control group (n = 65) P-value
Age (year) 59.91 ± 10.45 54.21 ± 13.67 0.008
Axial length (mm) 22.65 ± 0.87 22.72 ± 0.80 0.636
Spherical equivalent(D) 0.088 ± 0.425 0.049 ± 0.437 0.691
cpRNFL thickness (μm)
Beta zone area (mm²)
60.79 ± 13.99
0.97 ± 0.93
118.53 ± 15.47
0.41 ± 0.53
<0.001
<0.001
Gamma zone area (mm²) 0.073 ± 0.176 0.093 ± 0.183 0.517
Mean PCT (μm) 114.61 ± 42.24 124.33 ± 28.59 0.137
PCT nasal superior (μm) 114.02 ± 43.84 126.62 ± 32.67 0.064
PCT nasal (μm) 113.24 ± 40.56 121.08 ± 41.88 0.279
PCT nasal inferior (μm) 104.52 ± 49.00 116.32 ± 30.25 0.099
PCT temporal superior (μm) 119.79 ± 47.33 134.52 ± 39.20 0.054
PCT temporal (μm) 119.26 ± 48.41 116.56 ± 40.19 0.729
PCT temporal inferior (μm) 106.12 ± 49.79 118.76 ± 31.49 0.085

Main ocular parameters between chronic primary angleclosure glaucoma (CACG) and control eyes

Table 2.  

Parameter Univariate analysis Multivariate analysis
P-value Standardized coefficient beta P-value Standardized coefficient beta
Beta zone area
Age (year) <0.001 0.372 0.001 0.300
Axial length (mm) 0.182 0.119
CACG <0.001 0.349 0.016 0.228
Optic disc ovality index 0.858 0.016
BMO ovality ratio 0.108 −0.144
Mean PCT (μm)
cpRNFL thickness
0.002
<0.001
−0.280
−0.347
Central cornea thickness (μm) 0.003 −0.290 0.030 −0.199
Lens thickness (mm) 0.047 0.228
Gamma zone area
Age (year) 0.134 −0.132
Axial length (mm) 0.659 −0.040
CACG 0.517 −0.057
Optic disc ovality index <0.001 −0.404 <0.001 −0.926
BMO ovality ratio 0.001 0.287 <0.001 0.803
Mean PCT (μm) 0.501 0.061
cpRNFL thickness 0.505 0.059
Central cornea thickness (μm) 0.116 0.157
Lens thickness (mm) 0.750 0.037

Linear regression analysis of parameters associated with peripapillary beta zone area and gamma zone area

Table 3.  

PCT location Mean PCT(μm) Univariate analysis Multivariate analysis R²
Parameter P-value Parameter P-value
Temporal inferior 112.44 ± 41.75 Age <0.001 Age <0.001 0.220
Beta zone area 0.002
Temporal 117.90 ± 44.31 Age <0.001 Age <0.001 0.237
Temporal superior 127.21 ± 43.88 Age <0.001 Age 0.002 0.192
Beta zone area 0.001
Nasal superior 120.37 ± 38.98 Age <0.001 Age 0.002 0.254
Beta zone area 0.016
Nasal 117.13 ± 41.25 Age 0.003 Age 0.003 0.106
Nasal inferior 110.42 ± 40.77 Age <0.001 Age <0.001 0.229
Beta zone area 0.016

Parameters show significant association with peripapillary choroidal thickness (PCT) in univariate and multivariate linear regression

CME

Morphological Features of Parapapillary Beta Zone and Gamma Zone in Chronic Primary Angle-Closure Glaucoma

  • Authors: Kunte Shang, MD; Xinxin Hu, MD; Yi Dai, MD, PhD
  • CME Released: 8/30/2019
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 8/30/2020, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for ophthalmologists and other physicians who treat and manage patients with chronic primary angle-closure glaucoma (CACG).

The goal of this activity is to describe the morphological features of the parapapillary beta and gamma zone and associated factors in eyes with CACG, according to an observational cross-sectional study.

Upon completion of this activity, participants will:

  1. Describe morphological features of the parapapillary beta and gamma zone in eyes with CACG compared with nonmyopic control eyes, according to an observational cross-sectional study
  2. Determine factors associated with morphological features of the parapapillary beta and gamma zone, according to an observational cross-sectional study
  3. Identify pathophysiological implications of morphological features of the parapapillary beta and gamma zone in eyes with CACG, according to an observational cross-sectional study


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author(s)

  • Kunte Shang, MD

    Department of Ophthalmology & Visual Science
    Eye and ENT Hospital
    Shanghai Medical College
    Fudan University
    NHC Key Laboratory of Myopia (Fudan University)
    Laboratory of Myopia
    Chinese Academy of Medical Sciences
    Shanghai Key Laboratory of Visual Impairment and Restoration (Fudan University)
    Shanghai, China

    Disclosures

    Disclosure: Kunte Shang, MD, has disclosed no relevant financial relationships.

  • Xinxin Hu, MD

    Department of Ophthalmology & Visual Science
    Eye and ENT Hospital
    Shanghai Medical College
    Fudan University
    NHC Key Laboratory of Myopia (Fudan University)
    Laboratory of Myopia
    Chinese Academy of Medical Sciences
    Shanghai Key Laboratory of Visual Impairment and Restoration (Fudan University)
    Shanghai, China

    Disclosures

    Disclosure: Xinxin Hu, MD, has disclosed no relevant financial relationships.

  • Yi Dai, MD, PhD

    Department of Ophthalmology & Visual Science
    Eye and ENT Hospital
    Shanghai Medical College
    Fudan University
    NHC Key Laboratory of Myopia (Fudan University)
    Laboratory of Myopia
    Chinese Academy of Medical Sciences
    Shanghai Key Laboratory of Visual Impairment and Restoration (Fudan University)
    Shanghai, China

    Disclosures

    Disclosure: Yi Dai, MD, PhD, has disclosed no relevant financial relationships. 

Editor

  • Sobha Sivaprasad, MD

    Editor, Eye

    Disclosures

    Disclosure: Sobha Sivaprasad, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Heidelberg Pharma GmbH; Optos; Roche
    Served as a speaker or a member of a speakers bureau for: Allergan, Inc.; Bayer AG; Novartis Pharmaceuticals Corporation; Optos
    Received grants for clinical research from: Allergan, Inc.; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Optos

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships. 

CME Reviewer

  • Esther Nyarko, PharmD

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Springer Nature. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Eye
CME

Morphological Features of Parapapillary Beta Zone and Gamma Zone in Chronic Primary Angle-Closure Glaucoma

Authors: Kunte Shang, MD; Xinxin Hu, MD; Yi Dai, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 8/30/2019

Valid for credit through: 8/30/2020, 11:59 PM EST

processing....

Abstract and Introduction

Abstract

Purpose: To investigate the morphological features of parapapillary beta zone and gamma zone and their associated factors in eyes with chronic primary angle-closure glaucoma (CACG).

Methods: The observational cross-sectional study included 65 CACG eyes and 65 non-myopic control eyes. On enhanced depth imaging of optical coherent tomography images, the area of parapapillary beta zone and gamma zone, and the peripapillary choroidal thickness at 6 sectors were measured. The optic disc ovality index and Bruch's membrane opening (BMO) shape were further calculated.

Results: Beta zone was present in 103 (79.2%) eyes and gamma zone in 29 (22.3%) eyes. Compared to control eyes, CACG was associated with larger parapapillary beta zone, female gender, and older age (P < 0.01). No significant difference was observed in axial length and peripapillary choroidal thickness between both groups (P > 0.05). In multivariate analysis, beta zone area was positively associated with older age and higher prevalence of CACG (P < 0.01), while a larger gamma zone area was associated with a smaller disc ovality index and a higher BMO ovality ratio (P < 0.01). The peripapillary choroidal thickness at six sectors was decreased with older age (P < 0.01).

Conclusions: In mainly non-myopic subjects with or without CACG, larger parapapillary beta zone was correlated with older age and presence of glaucoma, while a larger parapapillary gamma zone was correlated with disc ovality but not with glaucoma. Parapapillary beta zone and gamma zone may play different roles in physiological and glaucomatous changes around optic nerve head.

Introduction

The conventional ophthalmoscopic beta zone[1] of parapapillary atrophy characterized by visible choroidal vessels and the sclera has recently been divided into two subzones: gamma zone and (new) beta zone.[2,3] Based on spectral domain optical coherence tomography (SD-OCT) findings, gamma zone could be distinguished as the parapapillary region free of Bruch's membrane, and beta zone could be distinguished by the presence of Bruch's membrane and absence of RPE. Both gamma zone and beta zone were whitish zones upon ophthalmoscopy, while a delicate color difference could be noticed to distinguish these two subzones occasionally.

Growing evidence has suggested that parapapillary beta zone was associated mainly with primary open angle glaucoma and to a lower degree with axial myopia, while parapapillary gamma zone was strongly correlated with axial myopia.[3-5] Studies on the characteristics of SDOCT defined parapapillary atrophy in eyes with primary angle-closure glaucoma have only scarcely been performed,[6] if at all. Moreover, the etiology of the parapapillary beta and gamma zone in glaucoma has remained elusive so far.

Using the enhanced depth imaging of SD-OCT technology, we therefore performed this study to investigate the morphological features of parapapillary beta zone and gamma zone and associated factors in eyes with chronic primary angle-closure glaucoma (CACG).